Message From the Editor-in-Chief
The Circulation Journal Official Impact Factor and the Most Frequently Cited Papers in 2023
2024 Volume 88 Issue 9 Pages 1350-1353
Details
2024 Volume 88 Issue 9 Pages 1350-1353
Dear Colleagues,
On behalf of the Circulation Journal, I would like to report its official 2023 Impact Factor and the related information in detail as follows:
I would like to report that Circulation Journal has earned an official 2023 Impact Factor of 3.1 (2022: 3.3). The official ranking places Circulation Journal the 67th among the 220 journals in the Cardiac & Cardiovascular Systems category in 2023 JCR Science Citation Index Expanded Edition (67th among the 143 journals in 2022). I would like to ask readers to use Circulation Journal papers as reference papers in your future submission of manuscripts to any journals.
The following papers, published in 2021–2022, are the top 34 most frequently cited papers in 2023, thereby substantially contributing to the 2023 Impact Factor of the Journal. Numbers in the parenthesis denote the number of citations in 2023.
1. (35) Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, et al; on behalf of the Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. Circ J 2021; 85: 2252–2291.
2. (32) Ide T, Kaku H, Matsushima S, Tohyama T, Enzan N, Funakoshi K, et al; the JROADHF Investigators. Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF). Circ J 2021; 85: 1438–1450.
3. (26) Hisatome I, Li P, Miake J, Taufiq F, Mahati E, Maharani N, et al. Uric acid as a risk factor for chronic kidney disease and cardiovascular disease: Japanese guideline on the management of asymptomatic hyperuricemia. Circ J 2021; 85: 130–138.
(26) Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, et al; on behalf of the Japanese Circulation Society and Japanese Heart Rhythm Society Joint Working Group. JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. Circ J 2022; 86: 1790–1924.
5. (25) Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, et al; on behalf of the JCS/JHRS Joint Working Group. JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. Circ J 2021; 85: 1104–1244.
(25) Saito S, Yamazaki S, Takahashi A, Namiki A, Kawasaki T, Otsuji S, et al; for the Disrupt CAD IV Investigators. Intravascular lithotripsy for vessel preparation in severely calcified coronary arteries prior to stent placement: Primary outcomes from the Japanese disrupt CAD IV study. Circ J 2021; 85: 826–833.
7. (22) Crea F, Montone RA, Rinaldi R. Pathophysiology of coronary microvascular dysfunction. Circ J 2022; 86: 1319–1328. (Review)
8. (18) Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, et al; on behalf of the Japanese Circulation Society Joint Working Group. JCS/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. Circ J 2021; 85: 1590–1689.
9. (17) Nakano S, Kohsaka S, Chikamori T, Fukushima K, Kobayashi Y, Kozuma K, et al; on behalf of the JCS Joint Working Group. JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease. Circ J 2022; 86: 882–915.
(17) Nakamura M, Yaku H, Ako J, Arai H, Asai T, Chikamori T, et al; on behalf of the Japanese Circulation Society Joint Working Group. JCS/JSCVS 2018 guideline on revascularization of stable coronary artery disease. Circ J 2022; 86: 477–588.
11. (15) Yamagishi M, Tamaki N, Akasaka T, Ikeda T, Ueshima K, Uemura S, et al; on behalf of the Japanese Circulation Society Working Group. JCS 2018 guideline on diagnosis of chronic coronary heart diseases. Circ J 2021; 85: 402–572.
12. (14) Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Sakata Y, et al; on behalf of the PARALLEL-HF Investigators. Efficacy and safety of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction: Results from the PARALLEL-HF study. Circ J 2021; 85: 584–594.
13. (13) Chew NW, Sia CH, Wee HL, Benedict LJ, Rastogi S, Kojodjojo P, et al. Impact of the COVID-19 pandemic on door-to-balloon time for primary percutaneous coronary intervention: Results from the Singapore Western STEMI network. Circ J 2021; 85: 139–149.
14. (11) Sun BJ, Park JH. Echocardiographic measurement of left atrial strain: A key requirement in clinical practice. Circ J 2022; 86: 6–13. (Review)
15. (10) Jang AY, Lim S, Jo SH, Han SH, Koh KK. New trends in dyslipidemia treatment. Circ J 2021; 85: 759–768. (Review)
(10) Zhou X, Nakamura K, Sahara N, Takagi T, Toyoda Y, Enomoto Y, et al. Deep learning-based recurrence prediction of atrial fibrillation after catheter ablation. Circ J 2022; 86: 299–308.
(10) Watanabe R, Nagashima K, Wakamatsu Y, Otsuka N, Yokoyama K, Matsumoto N, et al; for the AF Ablation Frontier Registry Investigators. Different determinants of the recurrence of atrial fibrillation and adverse clinical events in the mid-term period after atrial fibrillation ablation. Circ J 2022; 86: 233–242.
18. (9) Tilz RR, Meyer-Saraei R, Eitel C, Fink T, Sciacca V, Lopez LD, et al. Novel cryoballoon ablation system for single shot pulmonary vein isolation: The prospective ICE-AGE-X study. Circ J 2021; 85: 1296–1304.
(9) Nogami A, Kurita T, Kusano K, Goya M, Shoda M, Tada H, et al; on behalf of the Japanese Circulation Society / the Japanese Heart Rhythm Society Joint Working Group. JCS/JHRS 2021 guideline focused update on non-pharmacotherapy of cardiac arrhythmias. Circ J 2022; 86: 337–363.
(9) Yamashita Y, Maruyama Y, Satokawa H, Nishimoto Y, Tsujino I, Sakashita H, et al. Incidence and clinical features of venous thromboembolism in hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan. Circ J 2021; 85: 2208–2214.
(9) Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, et al; on behalf of the JCS/JHRS Joint Working Group. CORRIGENDUM: JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. Circ J 2021; 85: 1692–1700.
22. (8) Natsuaki M, Morimoto T, Shiomi H, Ehara N, Taniguchi R, Tamura T, et al; on behalf of the CREDOKyoto PCI/CABG Registry Cohort-3 Investigators. Application of the modified high bleeding risk criteria for Japanese patients in an all-corners registry of percutaneous coronary intervention: From the CREDOKyoto registry cohort-3. Circ J 2021; 85: 769–781.
(8) Ohta M, Hayashi K, Mori Y, Sato H, Noto T, Kawahatsu K, et al. Impact of frailty on bleeding events related to anticoagulation therapy in patients with atrial fibrillation. Circ J 2021; 85: 235–242.
(8) Akao M, Ogawa H, Masunaga N, Minami K, Ishigami K, Ikeda S, et al; for the Fushimi AF Registry Investigators. 10-year trends of antithrombotic therapy Status and outcomes in Japanese atrial fibrillation patients: The Fushimi AF Registry. Circ J 2022; 86: 726–736.
(8) Yang PS, Sung JH, Kim D, Jang E, Yu HT, Kim TH, et al. Frailty and the effect of catheter ablation in the elderly population with atrial fibrillation: A real-world analysis. Circ J 2021; 85: 1305–1313.
26. (7) Sawano M, Kohsaka S, Ishii H, Numasawa Y, Yamaji K, Inohara T, et al. One-year outcome after percutaneous coronary intervention for acute coronary syndrome: An analysis of 20,042 patients from a Japanese Nationwide Registry. Circ J 2021; 85: 1756–1767.
(7) Takahashi M. NLRP3 inflammasome as a common denominator of atherosclerosis and abdominal aortic aneurysm. Circ J 2021; 85: 2129–2136. (Review)
(7) Iwai S, Watanabe M, Okamura A, Kyodo A, Nogi K, Kamon D, et al. Prognostic impact of calcified plaque morphology after drug eluting stent implantation: An optical coherence tomography study. Circ J 2021; 85: 2019–2028.
(7) Yoshida J, Ikenaga H, Nagaura T, Utsunomiya H, Kawai M, Makar M, et al. Impact of percutaneous edge-to-edge repair in patients with atrial functional mitral regurgitation. Circ J 2021; 85: 1001–1010.
(7) Katsushika S, Kodera S, Nakamoto M, Ninomiya K, Kakuda N, Shinohara H, et al. Deep learning algorithm to detect cardiac sarcoidosis from echocardiographic movies. Circ J 2022; 86: 87–95.
(7) Yamashita D, Saito Y, Sato T, Matsumoto T, Saito K, Wakabayashi S, et al. Impact of PARIS and CREDO-Kyoto thrombotic and bleeding risk scores on clinical outcomes in patients with acute myocardial infarction. Circ J 2022; 86: 622–629.
(7) Matoba T, Sakamoto K, Nakai M, Ichimura K, Mohri M, Tsujita Y, et al. Institutional characteristics and prognosis of acute myocardial infarction with cardiogenic shock in Japan: Analysis from the JROAD/JROAD-DPC database. Circ J 2021; 85: 1797–1805.
(7) Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, et al; on behalf of the FOURIER Study Group. Efficacy and safety of long-term evolocumab use among Asian subjects: A subgroup analysis of the Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial. Circ J 2021; 85: 2063–2070.
(7) Ploumen EH, Buiten RA, Zocca P, Doggen CJ, Aminian A, Schotborgh CE, et al. First report of 3-year clinical outcome after treatment with novel Resolute Onyx stents in the randomized BIONYX trial. Circ J 2021; 85: 1983–1990.
The following papers are the top 40 most frequently cited papers among the 8,272 papers published in the Circulation Journal (2002–2023). Numbers in the parenthesis denote the number of citations.
1. (1441) Matsuzawa Y, Nakamura T, Takahashi M, Ryo M, Inoue S, Ikeda Y, et al. New criteria for ‘obesity disease’ in Japan. Circ J 2002; 66: 987–992. (Review)
2. (587) Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975–981.
3. (572) Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411–418. (Review)
4. (567) Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213–220. (Review)
5. (502) Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; on behalf of the J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF Study. Circ J 2012; 76: 2104–2111.
6. (453) Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010; 74: 818–826. (Review)
7. (434) Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010; 74: 2257–2262. (Review)
8. (364) Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J 2009; 73: 595–601. (Review)
9. (355) Inoue H, Atarashi H, Kamakura S, Koretsune Y, Kumagai K, Mitamura H, et al; JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. Circ J 2014; 78: 1997–2021.
10. (351) Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al; the Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. Circ J 2019; 83: 2084–2184.
11. (319) Ogawa H, Akasaka T, Hattori R, Inoue T, Kawashima S, Kawasuji M, et al; JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013): Digest version. Circ J 2014; 78: 2779–2801.
12. (303) Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015; 79: 495–502. (Review)
13. (284) Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007; 71: 536–539.
14. (280) Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928–933.
15. (268) Ando J, Yamamoto K. Vascular mechanobiology: Endothelial cell responses to fluid shear stress. Circ J 2009; 73: 1983–1992. (Review)
16. (252) Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al; on behalf of the Japanese Circulation Society Joint Working Group. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J 2019; 83: 1085–1196.
17. (247) Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al; for the JCARECARD Investigators. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893–1900.
18. (246) Tomiyama H, Yamashina A. Non-invasive vascular function tests: Their pathophysiological background and clinical application. Circ J 2010; 74: 24–33. (Review)
19. (245) Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ J 2008; 72: 489–491.
20. (244) Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684–1692.
21. (243) Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 2012; 76: 485–488.
22. (241) Ueyama T, Kasamatsu K, Hano T, Yamamoto K, Tsuruo Y, Nishio I. Emotional stress induces transient left ventricular hypocontraction in the rat via activation of cardiac adrenoceptors: A possible animal model of ‘Takotsubo’ cardiomyopathy. Circ J 2002; 66: 712–713.
23. (229) Kawai S, Kitabatake A, Tomoike H; Takotsubo Cardiomyopathy Study Group. Guidelines for diagnosis of Takotsubo (ampulla) cardiomyopathy. Circ J 2007; 71: 990–992.
24. (227) Swift DL, Lavie CJ, Johannsen NM, Arena R, Earnest CP, O’Keefe JH, et al. Physical activity, cardiorespiratory fitness, and exercise training in primary and secondary coronary prevention. Circ J 2013; 77: 281–292. (Review)
25. (223) Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006; 70: 1437–1442.
26. (216) Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J 2008; 72: 598–604.
27. (214) Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K, et al. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 2013; 77: 705–711.
28. (211) Ando M, Fukuda I, Ito M, Kobayashi T, Masuda M, Miyahara Y, et al; JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009): Digest version. Circ J 2011; 75: 1258–1281.
29. (209) Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: Approach to therapy. Circ J 2011; 75: 1287–1296. (Review)
(209) Ogura R, Hiasa Y, Takahashi T, Yamaguchi K, Fujiwara K, Ohara Y, et al. Specific findings of the standard 12-lead ECG in patients with ‘Takotsubo’ cardiomyopathy: Comparison with the findings of acute anterior myocardial infarction. Circ J 2003; 67: 687–690.
31. (203) Tomiyama H, Koji Y, Yambe M, Shiina K, Motobe K, Yamada J, et al. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J 2005; 69: 815–822.
32. (202) Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597–607. (Review)
33. (200) Kamakura T, Makiyama T, Sasaki K, Yoshida Y, Wuriyanghai Y, Chen J, et al. Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ J 2013; 77: 1307–1314.
34. (199) Takigiku K, Takeuchi M, Izumi C, Yuda S, Sakata K, Ohte N, et al. Normal range of left ventricular 2-dimensional strain: Japanese ultrasound speckle tracking of the left ventricle (JUSTICE) study. Circ J 2012; 76: 2623–2632.
35. (198) Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J 2013; 77: 1111–1122. (Review)
(198) Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, et al. Pulse wave velocity predicts cardiovascular mortality: Findings from the Hawaii-Los Angeles-Hiroshima study. Circ J 2005; 69: 259–264.
37. (197) Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome: Randomized, double-blind, phase III PHILO study. Circ J 2015; 79: 2452–2460.
(197) Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: A pilot study. Circ J 2012; 76: 1750–1760.
39. (191) Nohara R, Adachi H, Goto Y, Hasegawa E, Ishihara S, Itoh H, et al; JCS Joint Working Group. Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012): Digest version. Circ J 2014; 78: 2022–2093.
40. (189) Ogawa H, Akasaka T, Hattori R, Kawashima S, Kawasuji M, Kimura K, et al; JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): Digest version. Circ J 2010; 74: 1745–1762.
The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.
